Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BDB018 |
Synonyms | |
Therapy Description |
BDB018 acts an an agonist of TLR7 and TLR8, potentially resulting in activation of the anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BDB018 | BDB 018|BDB-018 | TLR7 Agonist 12 TLR8 Agonist 9 | BDB018 acts an an agonist of TLR7 and TLR8, potentially resulting in activation of the anti-tumor immune response and tumor cell lysis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04840394 | Phase I | BDB018 BDB018 + Pembrolizumab | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |